Convalescent Plasma Restores Viral Clearance After Anti-Spike Monoclonal Antibody Failure in Immunocompromised COVID-19 Patients: A Systematic Review and Meta-Analysis of Individual Patient Data.
Daniele Focosi, Tommaso Francesco Aiello, Arturo Casadevall et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the effectiveness of convalescent plasma (CCP) in immunocompromised COVID-19 patients who remained positive for SARS-CoV-2 after anti-Spike monoclonal antibody (mAb) therapy. Among 47 patients, 70.2% achieved viral clearance following CCP transfusion, with an average of 2.7 units administered. The study highlights the potential role of CCP in managing resistant infections in this vulnerable population.
Key findings
- 70.2% of patients achieved SARS-CoV-2 clearance after CCP transfusion.
- A mean of 2.7 CCP units was administered per patient.
- Total CCP volume transfused was positively associated with viral clearance.
Why it matters
The findings suggest that convalescent plasma may be a viable treatment option for immunocompromised patients who do not respond to monoclonal antibody therapy, addressing a critical gap in managing persistent COVID-19 infections.